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Oral Factor Xa (FXa) inhibitors, a growing class of direct-acting anticoagulants, are frequently used to
prevent stroke and systemic embolism in patients with atrial ﬁbrillation and to prevent and treat venous
thromboembolism. These drugs reduce the risk of clotting at the expense of increasing the risk of bleeding,
and currently they have no speciﬁc reversal agent. However, andexanet alfa, a recombinant modiﬁed FXa
decoy molecule, is in a late-phase clinical trial in bleeding patients, and ciraparantag, a small molecule that
appears to reverse many anticoagulants including the FXa inhibitors, is in development. This review
summarizes the published data to date on both drugs, which have the potential to change the management
approach to patients with FXa inhibitoreassociated major hemorrhage.
 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2016) 129, S80-S88
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.1016/j.amjmed.2016.06.009consistently have been shown to be noninferior to warfarin
in clinical trials evaluating their safety and efﬁcacy.1-7 As
with any anticoagulant, these drugs incrementally increase
the risk of bleeding to greatly reduce the risk of clotting (eg,
stroke and venous thromboembolism). Before the U.S. Food
and Drug Administration’s (FDA) approval of idar-
ucizumab, a speciﬁc reversal agent for the direct thrombin
inhibitor dabigatran, the lack of reversal agents was a
consistent concern associated with the use of all direct-
acting oral anticoagulants. Currently, there is no approved
speciﬁc reversal agent for FXa inhibitors, although late-
phase clinical trials of reversal agents are ongoing.8
Warfarin anticoagulation historically has been reversed
with vitamin K1 (to reinitiate synthesis of affected factors II,
VII, IX, and X, along with proteins C and S) and fresh-frozen
plasma (to replete these factors more immediately),9 although
the effectiveness of this approach has not been demonstrated
in clinical trials. Despite being approved for human use in the
1950s in the United States, warfarin had no fast-acting,
speciﬁc reversal agent supported by evidence from a
randomized controlled trial until 2013, when a 4-Factor
prothrombin complex concentrate (PCC) was approved.10-12
The ﬁrst oral FXa inhibitor, rivaroxaban, was approved
in the United States in 2011,13 by which time reversal agents
for direct-acting oral anticoagulants were already inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Figure 1 Design of andexanet alfa. Serine, the active site of FXa, was substituted with alanine,
rendering the molecule unable to cleave and activate prothrombin. The Gla domain of FXa was
removed to prevent its assembly into the prothrombinase complex, thus removing any anticoagulant
effects. Gla ¼ gamma-carboxyglutamic acid-rich. Reproduced with permission from Portola Phar-
maceuticals, Inc (South San Francisco, Calif).
Table 1 FXa and “Universal” Reversal Agent Drug Targets
Anticoagulant Andexanet Ciraparantag
FXa
Apixaban U U
Edoxaban U U
Rivaroxaban U U
FIIa
Dabigatran — U
Heparin
UFH U U
LMWH U U
ATIII-FXa
Fondaparinux Unknown U
VKA
Warfarin — —
ATIII-FXa ¼ antithrombin III factor Xa; FIIa ¼ factor IIa; FXa ¼ factor
Xa; LMWH ¼ low-molecular-weight heparin; UFH ¼ unfractionated heparin;
VKA ¼ vitamin K antagonist.
Adapted from Lu et al,20,21 Crowther et al,22 and Sullivan et al.23
Milling and Kaatz Factor Xa and “Universal” Reversal Agents S81development. The FXa inhibitors apixaban14 and edoxaban15
have since been approved, andmore are in development (note
that all FXa inhibitors have the sufﬁx “Xa-ban” [Ten-A-Ban]
to denote their mechanism of action).
Preclinical and clinical data on 2 reversal agents,
andexanet alfa (Portola Pharmaceuticals, South San Francisco,
Calif), a recombinant modiﬁed FXa decoy molecule, and
ciraparantag (PER977, Perosphere Pharmaceuticals, Danbury,
Conn), a small molecule, will be covered in this review.
Idarucizumab, a speciﬁc reversal agent to dabigatran, is
covered in other chapters16-18 of this special issue. Off-label
use of factor products, for example, PCCs or recombinant
FVIIa, to treat bleeding in patients who have been anti-
coagulated with direct-acting oral anticoagulants is covered
elsewhere19 in this special issue.
ANDEXANET ALFA
Pharmacology
Lu et al,20 from Portola, published a proof-of-concept article
on andexanet alfa in 2013, describing the molecule as a
truncated form of enzymatically inactive FXa. In the coagu-
lation cascade, FXa joins factor Va (FVa) to form the pro-
thrombinase complex, which cleaves prothrombin (factor II
[FII]) to thrombin (factor IIa [FIIa]), which in turn cleaves
ﬁbrinogen to ﬁbrin. Two elegant modiﬁcations were made to
native human FXa to create andexanet (Figure 1). First, the
substitution of a serine residue with an alanine at the active
site eliminates the protein’s catalytic activity, that is, its
ability to cleave prothrombin to thrombin. Second, the
removal of the Gla (carboxyglutamic acid) domain
eliminates its ability to assemble into the prothrombinase
complex, thus removing any anticoagulant effect through the
prevention of binding native FVa and inhibiting prothrombin
activation. The molecule retains its ability to bind direct FXa
inhibitors (the Xabans), but it also binds to low-molecular-
weight heparins (LMWH), pentasaccharide-activated anti-
thrombin III (ATIII), and unfractionated heparin, and thereby
alters the activity of these indirect FXa inhibitors
(Table 1).20,21 Investigators recently reported robust double-
blind, placebo-controlled safety and biomarker reversal dataon nonbleeding older volunteers.24 A summary of the pre-
clinical and clinical studies of andexanet is shown in Table 2
and discussed in further detail in this review.Preclinical Animal Studies and Human Blood
in Vitro Studies
The seminal article by Lu et al20 demonstrated a rapid effect
of andexanet, which appeared to reverse direct FXa in-
hibitors completely in human and rat plasma and to restore
hemostasis and reduce bleeding in mouse tail transection
and rabbit liver laceration models. In humans, andexanet has
an effective half-life of approximately 1 hour, which de-
pends on the dose of andexanet and the particular FXa in-
hibitor with which it is used.24 The FDA granted Portola
breakthrough therapy designation, intended to expedite the
development and review of drugs for serious or life-
threatening conditions, for andexanet in 2013.33
Beyond the primary effect of reestablishing hemostatic
efﬁcacy, there are 2 major safety concerns, one general to all
anticoagulant “reversal” agents and one speciﬁc to the
Table 2 Summary of Preclinical and Clinical Studies of Andexanet
Enoxaparin Dabigatran Rivaroxaban Apixaban Edoxaban
Animal in vivo
Rat tail transection Decreased bleeding
by >50%25
e e e e
Mouse tail transection e e Decreased bleeding by
>80% (þ ASA)26
e
Rabbit liver laceration e e Decreased bleeding
by >80%27
e
Human in vitro
e e Dose-dependent reversal
of anti-FXa activity in a
buffer system of puriﬁed
human FXa; reversal of
direct and ATIII-
dependent FXa
inhibitors in human
plasma28
Anti-FXa activity of
exogenous rivaroxaban
was reduced in human
plasma from healthy
subjects pre-treated
with andexanet29
Dose-dependent reversal
of anti-FXa activity in a
buffer system of puriﬁed
human FXa; reversal of
direct and ATIII-
dependent FXa
inhibitors in human
plasma28
Dose-dependent
reversal of anti-
FXa activity in a
buffer system of
puriﬁed human
FXa; reversal of
direct and ATIII-
dependent FXa
inhibitors in
human plasma28
Human in vivo
Reversal of anti-FXa
activity in healthy
subjects22
e Reversal of anti-FXa
activity in healthy
subjects22
Dose-dependent reversal
of anti-FXa activity in
healthy subjects and
partial restoration of
thrombin generation
and partial reversal of
prolongation of clotting
time30
Sustained reversal of anti-
FXa activity with bolus
plus infusion in healthy
older subjects24
Reversal of anti-FXa
activity in healthy
subjects22
Sustained reversal of
anti-FXa activity with
bolus plus infusion in
healthy subjects31
Sustained reversal of
anti-FXa activity with
bolus plus infusion in
healthy older subjects24
Dose-dependent
reversal of anti-
FXa activity in
healthy subjects
and restoration
of thrombin
generation and
reversal of
prolongation of
clotting time.32
ASA ¼ acetylsalicylic acid; ATIII ¼ antithrombin III; FXa ¼ factor Xa.
S82 The American Journal of Medicine, Vol 129, No 11A, November 2016andexanet approach, neither of which has been demon-
strated despite ongoing surveillance. Generally, reversal
agents must effectively restore hemostasis without creating
excessive rebound hypercoagulable states and risk for
clinically signiﬁcant thromboembolic events. Speciﬁc to
andexanet alfa, a modiﬁed clotting factor must not lead to an
antibody response against its native cousin, potentially
causing an iatrogenic clotting factor deﬁciency.Clinical Studies
In a phase 2 dose-ranging, proof-of-concept study in
healthy, nonbleeding volunteers treated with apixaban,
rivaroxaban, the LMWH enoxaparin,22 or edoxaban,32
andexanet demonstrated rapid (within 2 minutes)34,35
reversal of anticoagulation activity, as measured byanti-FXa activity assays; anti-FXa activity returned to pla-
cebo levels in approximately 2 hours after treatment in the
study of reversal of edoxaban-induced anticoagulation.32
The reversal could be extended with a continuous infu-
sion.22 There were no observed thrombotic events, serious
adverse events, discontinuation because of adverse events,
or antibodies to endogenous human FXa or FX.22,32
Andexanet has since been studied in phase 3, double-
blind, placebo-controlled studies as a single bolus or a
bolus plus 2-hour infusion in nonbleeding healthy older
adults (50-75 years) treated with apixaban or rivaroxaban.24
Andexanet was administered as a bolus plus 2-hour infusion
because the half-life of the drug is approximately 1 hour
(Figure 2). The apixaban and rivaroxaban groups were
administered 400 or 800 mg of andexanet, respectively;
doses were selected on the basis of the stoichiometric ratio
0
0 0.2 0.4 0.6 2
Hours Since Bolus
4
Andexanet (n = 24)
Placebo (n = 9)
A Apixaban Study, Andexanet Bolus
6 8 10 12
2.5
5.0
7.5
U
nb
ou
nd
 A
pi
xa
ba
n 
(n
g/
m
L) 10.0
12.5
End of
bolus
0
0 0.2 0.4 0.6 2
Hours Since Bolus
4
Andexanet (n = 23)
Placebo (n = 8)
C Apixaban Study, Andexanet Bolus plus Infusion
6 8 10 12
2.5
5.0
7.5
U
nb
ou
nd
 A
pi
xa
ba
n 
(n
g/
m
L)
10.0
12.5
End of
bolus
End of
infusion
0
0 0.2 0.4 0.6 2
Hours Since Bolus
4
Andexanet (n = 27)
Placebo (n = 14)
B Rivaroxaban Study, Andexanet Bolus
6 8 10 12
10
20
U
nb
ou
nd
 R
iv
ar
ox
ab
an
 (n
g/
m
L)
30
End of
bolus
0
0 0.2 0.4 0.6 2
Hours Since Bolus
4
Andexanet (n = 26)
Placebo (n = 13)
D Rivaroxaban Study, Andexanet Bolus plus Infusion
6 8 10 12
10
20
30
U
nb
ou
nd
 R
iv
ar
ox
ab
an
 (n
g/
m
L)
40
End of
bolus
End of
infusion
Figure 2 Time courses of plasma concentrations of unbound apixaban or rivaroxaban before and
after administration of andexanet. Concentrations of unbound apixaban or rivaroxaban in plasma were
measured before and after administration of andexanet or placebo on study day 4. (A) Data from
participants in the apixaban study who received andexanet, as a 400-mg intravenous bolus, or placebo.
(B) Participants in the rivaroxaban study who received andexanet, as an 800-mg intravenous bolus, or
placebo. (C) Participants in the apixaban study who received andexanet, as a 400-mg intravenous bolus
plus a 4-mg-per minute infusion for 120 minutes, or placebo. (D) Participants in the rivaroxaban study
who received andexanet, an 800-mg intravenous bolus plus an 8-mg-per minute infusion for 120
minutes, or placebo. The dashed horizontal line represents the calculated no-effect level for antico-
agulant activity (3.5 ng/mL of apixaban and 4.0 ng/mL of rivaroxaban). The points on the graph
represent the mean unbound inhibitor plasma concentrations, and I bars indicate the standard error.
There was a signiﬁcant difference (P < .05) between andexanet and placebo until 2 hours after the end
of the bolus and 1 hour after the end of the infusion in the apixaban study and until 3 hours after the
end of the bolus and 3 hours after the end of the infusion in the rivaroxaban study. Reprinted with
permission from Massachusetts Medical Society.24
Milling and Kaatz Factor Xa and “Universal” Reversal Agents S83needed for the reversal of each anticoagulant. In the
apixaban group, anti-FXa activity was reduced by 94% in
subjects (n ¼ 24) who received an andexanet bolus versus
21% in participants (n ¼ 9) who received placebo
(P < .001), and the concentration of unbound apixaban
was reduced by 9.3 ng/mL versus 1.9 ng/mL (P < .001);
thrombin generation was fully restored within 2 to 5
minutes in 100% versus 11% of subjects (P < .001)
(Figure 2A).24 In the rivaroxaban group, anti-FXa activity
was reduced by 92% in subjects (n ¼ 27) who received an
andexanet bolus versus 18% in subjects (n ¼ 14) who
received placebo (P < .001), and the concentration of un-
bound rivaroxaban was reduced by 23.4 ng/mL versus
4.2 ng/mL (P < .001); thrombin generation was fullyrestored in 96% versus 7% of subjects (P < .001)
(Figure 2B).24 When andexanet was administered as a bolus
plus 2-hour infusion, these effects were sustained in subjects
treated with apixaban and rivaroxaban (Figure 2C and D).
Transient increases in levels of D-dimer and prothrombin
fragments 1 and 2 (F1.2) occurred in a subgroup of
subjects, raising a concern for prothrombotic effect, but
this normalized within 24 to 72 hours.24 Mild infusion re-
actions were reported in some subjects, and 1 subject
developed hives.24 Subjects were followed for 6 weeks, and
there were no serious adverse events, thromboembolic
events, or neutralizing antibody development.24
The pivotal Andexanet Alfa a Novel Antidote to the Anti-
coagulant Effects of FXa Inhibitors (ANNEXA)-4 trial
S84 The American Journal of Medicine, Vol 129, No 11A, November 2016(NCT02329327)36 is now under way, with a goal of enrolling
270 bleeding patients. It is the ﬁrst to study andexanet in
bleeding humans and shares some similarities with the trials of
the 4-Factor PCC for warfarin reversal.10,11 One major differ-
ence is the lack of a control group (eg, plasma in the 4-Factor
PCC trials). Because there is no standard of care for reversing
these drugs, and thus no reasonable active control, it would not
be ethical or feasible to give placebos to patients with major
hemorrhages. The same reasoning accounts for the single-arm
design in the idarucizumab study, REVERSal Effects of Idar-
ucizumabonActiveDabigatran (RE-VERSEAD).37One of the
ANNEXA-4 study’s primary outcomes is clinical hemostatic
efﬁcacy36 similar to a scale developed for the 4-Factor PCC
trials,10 and safety outcomes also are being gathered. The trial
may take several years to enroll its cohort, but given its FDA
breakthrough designation, the drug could be approved before
completion, as was the case with idarucizumab.
It isworthnoting that there are somekeydifferencesbetween
the ANNEXA-4 study36 and the study of idarucizumab for the
reversal of dabigatran in the RE-VERSE AD trial.37 The
ANNEXA-4 study strictly requires that subjects meet major
hemorrhage criteria for inclusion, and it excludes participation
in the efﬁcacy analysis if patients do not meet these criteria.36
Therefore, a strength of the ANNEXA-4 study is that it in-
cludes patients with well-characterized major hemorrhage who
are in needof immediate reversal.36 In contrast,RE-VERSEAD
was more permissive, allowing physician discretion on who
required immediate reversal therapy and thus was designed to
mimic a “real-world” population.37 In addition, the primary end
point of the RE-VERSE AD study was the percentage reversal
of the anticoagulant effect of dabigatran. This calculation
included the measurements of dilute thrombin time or ecarin
clotting time, both of which correlate consistently with the
concentration of unbound dabigatran across a wide range of
dabigatran concentrations. The ANNEXA-4 study uses dual
primary outcomes of a biomarker (anti-FXa levels) plus a
clinical outcome of hemostatic efﬁcacy.36,38CIRAPARANTAG
Pharmacology
Perosphere is developing ciraparantag (di-arginine piperazine;
formerly known as “aripazine” or “PER977”). Ciraparantag is
a small (512 Da) synthetic molecule that reportedly binds toFigure 3 Molecular structure of ciraparantag. Runfractionated heparin, LMWH fondaparinux, and the
direct-acting oral anticoagulants dabigatran, rivaroxaban,
apixaban, and edoxaban23,39,40 (Table 1). It inactivates
anticoagulants via noncovalent hydrogen binding, which
blocks the binding to the target sites of FIIa and FXa. It
does not bind to coagulation factors or other plasma
proteins23,41,42 and has no measurable prothrombotic effect
as measured by D-dimer, F1.2, or tissue factor pathway in-
hibitor.43 The chemical structure of ciraparantag is shown in
Figure 3. A summary of the preclinical and clinical studies of
ciraparantag is shown in Table 3 and discussed in further
detail in this review.Preclinical Animal Studies
Laboratory rats were dosed with edoxaban and followed by
ciraparantag or saline in 3 models: tail transection, liver
laceration, and measurement of whole blood clotting time.
Ciraparantag decreased bleeding within 7.5 minutes in the
tail transection model, within 10 minutes in the liver
laceration model,45 and within 30 minutes in the whole
blood clotting time model.46 Ciraparantag also has been
shown to reduce bleeding from tail transection by more than
90% in rats overdosed with dabigatran, rivaroxaban, or
apixaban.39
Andexanet manufacturer Portola synthesized cirapar-
antag and compared the reversal effects in a rabbit liver
laceration model with prior studies with andexanet.47 High-
dose ciraparantag reversed blood loss to a similar extent as
andexanet. In nonanticoagulated rabbits, there was a
reduction in blood loss suggesting ciraparantag may have
procoagulant effects, although this trend was not statistically
signiﬁcant. Ciraparantag required a 30:1 molar ratio
(compared with 1:1 with andexanet), consistent with the
difference in mechanism of action.Preclinical Human Blood In Vitro Studies
Rivaroxaban or apixaban was added to plasma from healthy
human volunteers at 1 and 2 times the therapeutic maximum
concentration.39 The effect of ciraparantag on anti-FXa ac-
tivity was measured by a chromogenic assay, and rivarox-
aban and apixaban anti-FXa activity were completely
reversed in a dose-dependent manner.eprinted with permission from Ansell et al.44
Table 3 Summary of Preclinical and Clinical Studies of Ciraparantag
Enoxaparin Dabigatran Rivaroxaban Apixaban Edoxaban
Animal in vivo
Rat tail transection e Decreased
bleeding
by >90%39
Decreased bleeding
by >90%39
Decreased bleeding
by >90%39
Decreased bleeding45,48
Rat liver laceration e e e e Decreased bleeding,
reversed change in
WBCT, and normalized
clot ﬁbrin diameter45,46
Rabbit liver laceration e e e e Decreased bleeding
by up to 76%47
Human in vitro
e e Dose-dependent
reversal of anti-
FXa levels in
spiked
plasma39,48
Dose-dependent
reversal of anti-FXa
levels in spiked
plasma39,48
e
Human in vivo
Increase in WBCT
reversed within
5 min43
e e e Dose-dependent
reversal of increase
in WBCT44
No procoagulation
detected by D-dimer,
F1.2, or TFPI43
F1.2 ¼ prothrombin fragments 1 and 2; FXa ¼ factor Xa; TFPI ¼ tissue factor pathway inhibitor; WBCT ¼ whole blood clotting time.
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Forty healthy subjects were given enoxaparin 1.5 mg/kg,
and 4 hours later they received placebo or 100 mg, 200 mg,
or 300 mg of ciraparantag, and whole blood clotting timesPER977
administered
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Figure 4 Effect of PER977 (ciraparantag) on whole
blood clotting times after administration of a single o
later by a single intravenous dose of 25 mg, 100 mg
Reprinted with permission from Massachusetts Medicwere measured.43 Of note, enoxaparin increased whole
blood clotting time by 28.5%  3.3%. Ciraparantag
completely reversed the increase in whole blood clotting
time within 20 minutes in subjects receiving 100 mg and60 mg Edoxaban
Pooled Placebo
25 mg PER977
100 mg PER977
300 mg PER977
*P < .05 vs placebo
tration
18 21 24 27
-blood clotting time. Shown are the mean whole
ral 60-mg dose of edoxaban, followed 3 hours
, or 300 mg PER977 (ciraparantag) or placebo.
al Society.44
Figure 5 Dose-dependent normalization of ﬁbrin diameter with ciraparantag (PER977) in human volunteers treated with edoxaban.
Top: Clot ﬁbrin structure pre- and post-ciraparantag (upper and lower photographs represent lower and higher magniﬁcation). Bottom:
Computer algorithm-based quantiﬁcation of clot ﬁbrin diameter. IV ¼ intravenous; PO ¼ oral. Reprinted with permission from
Massachusetts Medical Society.44
S86 The American Journal of Medicine, Vol 129, No 11A, November 2016within 5 minutes with the 200-mg dose, and the effect was
sustained for 24 hours. There was no signal for hyperco-
agulability as measured by D-dimer, F1.2, or tissue factor
pathway inhibitor.
In a dose-escalation study, 80 healthy volunteers were
divided into 8 cohorts, each with a different dose (5, 15, 25 [2
cohorts], 50, 100, 200, or 300 mg of ciraparantag).44
All patients received 60 mg of edoxaban and were random-
ized in an 8:2 ratio to ciraparantag or placebo 3 hours after
edoxaban administration. Edoxaban increased whole blood
clotting time by 37% over baseline, and ciraparantag 100 mg
and 300 mg reduced this to within 10% of baseline within 10
minutes, and the effect persisted for 24 hours (Figure 4).
Subjects receiving placebo required approximately 12 to 15
hours to decrease whole blood clotting times to within 10%of baseline. Mean ﬁbrineﬁber diameter was determined
from analyzing scanning electron micrographs of clots
using a computer algorithm (Figure 5). Edoxaban
decreased the mean ﬁbrineﬁber diameter from
approximately 250 nm to 125 nm, and the diameter was
restored within 30 minutes of ciraparantag doses that had
been shown to reverse elevation in whole blood clotting
times. There was no evidence of hypercoagulability as
measured by changes in D-dimer, F1.2, tissue factor
pathway inhibitor, or whole blood clotting time. Potentially
ciraparantag-related adverse reactions included transient
mild perioral and facial ﬂushing, dysgeusia, and headache.
One subject had moderate muscle cramping and elevated
post-treatment creatinine phosphokinase levels, but these
events were not considered to be related to the study drug.
Milling and Kaatz Factor Xa and “Universal” Reversal Agents S87Ciraparantag is being developed as a “universal” anti-
coagulant reversal agent to block the anticoagulant effect of
unfractionated heparin, LMWH, fondaparinux, and the new
direct oral anticoagulants (Table 1), and the FDA has
granted fast-track designation to its development.49
CONCLUSIONS
At the present time, there are no speciﬁc reversal agents
available for the direct oral FXa inhibitors. Emerging data
from early-phase studies of andexanet alfa and cirapar-
antag are encouraging, and phase 3 studies in patients
who require reversal for signiﬁcant bleeding or urgent
invasive procedure/surgery are eagerly anticipated.
Approximately 50 years elapsed before there were
randomized controlled trial data demonstrating the efﬁ-
cacy and safety of a rapid onset reversal agent for
warfarin. Current developments are encouraging that pa-
tients taking oral anti-FXa anticoagulants will not have to
wait as long.
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